Distinct safety profiles of liposomal and conventional irinotecan: insights from clinical experience and real-world data.
Clinical evidence update from Frontiers in pharmacology
Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for production animal practice, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Frontiers in pharmacology in 2026 evaluated distinct safety profiles of liposomal and conventional irinotecan: insights from clinical experience and real-world data..
Key Findings
Liposomal irinotecan (nal-IRI) and conventional irinotecan (IRI) represent two formulations with distinct pharmacokinetic properties, yet their comparative safety profiles remain incompletely characterized. This study aimed to systematically evaluate their adverse event (AE) patterns through integrated pharmacovigilance and clinical analyses. We conducted a dual-approach investigation combining: (1) a single-center retrospective study of 308 pancreatic cancer patients (nal-IRI = 131; IRI = 177) treated between December 2023-September 2024, and (2) disproportionality analysis of FAERS database reports (2004-2024) using reporting odds ratios...
Why It Matters for Veterinary Professionals
For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for production animal practice.
Practical Interpretation
The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.
Clinical Takeaway
Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.
Read the full article here.
Comments
Related Articles
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment